 Targacept Inc said it would abandon further development of TC as a treatment for overactive bladder after seeing disappointing results in a midstage study The results were not compelling enough to justify the compounds continued development in overactive bladder said Dr Stephen A Hill the companys president and chief executive officer  Shares
  